Determination of glucocorticoid receptors in human leukemias.
Determination of steroid receptors has been used to predict steroid sensitivity in various neoplasias. In an attempt to investigate its applicability in human leukemias we have studied glucocorticoid receptors in the leukemic cells from 23 patients with various hematologic neoplasias and in the lymphocytes from 18 normal donors. Specific glucocorticoid binding in intact cells was determined by a whole cell competitive binding assay. Normal lymphocytes have about 4,611 specific binding sites per cell. The blasts from 9 patients with acute myelogenous leukemias (AML) have strongly varying high levels of specific binding sites, ranging from 4,817 to 15,416 per cell. Of the 13 patients with chronic lymphocytic leukemia (CLL), 5 have received glucocorticoid treatment for years and were  clinically resistant to glucocorticoid. Their lymphocytes have lower specific binding sites (range: 2,047 to 3,999) than the other CLL cases which were newly diagnosed (range: 3,734 to 11,020). Our results suggest that determination of glucocorticoid receptors might be of value in predicting clinical responsiveness in leukemias.
D003907:Dexamethasone / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007962:Leukocytes / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D011965:Receptors, Glucocorticoid / Q000032:analysis*; D011987:Receptors, Steroid / Q000032:analysis*
D011965:Receptors, Glucocorticoid; D011987:Receptors, Steroid; D003907:Dexamethasone